Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients

  • Authors:
    • Tomoyuki Suehiro
    • Hisamitsu Miyaaki
    • Yasuko Kanda
    • Hidetaka Shibata
    • Takuya Honda
    • Eisuke Ozawa
    • Satoshi Miuma
    • Naota Taura
    • Kazuhiko Nakao
  • View Affiliations

  • Published online on: June 19, 2018     https://doi.org/10.3892/ol.2018.8991
  • Pages: 3267-3273
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Exosomal microRNAs (miRNAs) have been investigated as potential novel biomarkers, and miR‑122 and miR‑21 were shown to be important in hepatocellular carcinoma (HCC). We analyzed the importance of serum exosomal miRNA expression levels in HCC patients that underwent transarterial chemoembolization (TACE). Seventy‑five HCC patients who underwent TACE as the initial treatment in Nagasaki University Hospital were enrolled. Exosomal miRNAs were isolated from serum samples collected before and after TACE. Exosomal miR‑122 expression levels significantly decreased after TACE (P=0.012), while the exosomal miR‑21 expression levels did not significantly change. The expression levels of exosomal miR‑122 before TACE were shown to correlate significantly with aspartate aminotransferase (r=0.31, P=0.004) and alanine aminotransferase (r=0.33, P=0.003) levels, tumor diameter (r=0.29, P=0.010) and Child‑Pugh score (r=‑0.28, P=0.013). The median survival time for all patients was 47 months, and neither of the investigated exosomal miRNAs were shown to be independent factors associated with the disease‑specific survival. According to the median relative expression of miR‑122 after TACE/before TACE (miR‑122 ratio) in liver cirrhosis patients (n=57), the patients with a higher miR‑122 ratio had significantly longer disease‑specific survival, compared with that of the patients with the lower miR‑122 ratio (P=0.0461). Multivariate Cox proportional hazards regression analysis of clinical parameters revealed that a lower exosomal miR‑122 ratio (HR 2.720; 95% confidence interval, 1.035‑8.022; P=0.042) is associated with the disease‑specific survival. Taken together, our results demonstrate that the exosomal miR‑122 level alterations may represent a predictive biomarker in HCC patients with liver cirrhosis treated with TACE.

Introduction

Hepatocellular carcinoma (HCC) develops from chronic liver diseases and it represents a common cancer type worldwide, with high incidence in East and South Asia (1,2). Various HCC treatments exist, such as resection, radiofrequency ablation, irradiation, and chemotherapy, but transarterial chemoembolization (TACE) is usually performed (3,4), as this selective intervention may result in a favorable clinical course (5). However, the prognosis of multiple HCCs remains poor due to a high recurrence rate and resistance to chemotherapy (6). In order to improve the disease prognosis and evaluate the effectiveness of TACE, the identification of non-invasive predictive biomarkers is required.

MicroRNAs (miRNAs) are small non-coding RNAs (17–23 nucleotides) that regulate mRNA post-transcriptionally, and many miRNAs have been reported to be potential predictive biomarkers (7). miR-122 is one of the miRNAs highly expressed in liver (8), and a decrease in its expression in HCC patients was shown to be associated with hepatocarcinogenesis and poor prognosis (9). Additionally, cyclin G1, a disintegrin and metalloprotease 17 (ADAM17), and IGF1R are the targets of miR-122 (10), shown to be downregulated in HCC tissues (11). In contrast, miR-21 was shown to be overexpressed in some malignancies, and it plays an important role in cell proliferation, invasion, and migration, by suppressing PTEN expression (12).

Exosomes are extracellular vesicles, 40–100 nm large, which can contain different molecules, including proteins, DNA, RNA, and miRNAs, but their content does not necessarily mirror the RNA expression profile and can change in response to cellular conditions (13). Although the exosomal miRNAs found in patient sera were shown to be associated with the clinical features in different malignances (14,15), TACE-induced changes in the exosomal miRNA expression levels remain unknown. Therefore, we hypothesized that the exosomal miR-122 and miR-21 may play a key role in HCC development and progression and investigated whether the exosomal miRNA ratio can be used as a predictive marker in HCC patients treated with TACE.

Materials and methods

Patients and samples

Seventy-five HCC patients who underwent TACE as the initial treatment at Nagasaki University Hospital (Nagasaki, Japan) from January 2006 to March 2013 were enrolled in this study. This study was approved by the Research Ethics Committee of Nagasaki University Hospital, and we obtained informed consent from all patients. Liver function before the treatment was preserved in all patients, and patients with Child-Pugh grade C or with the portal vein obstruction due to tumor thrombosis were excluded from the study. We used the Barcelona Clinic Liver Cancer staging classification (BCLC) for clinical staging. The average age at the treatment was 73 (range, 38–89) and the number of patients with liver cirrhosis (LC) was 57 (76%) and with chronic hepatitis, 18 (24%) (Table I). HCC patients were diagnosed by using contrast-enhanced-computed tomography (CE-CT) or Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI), which revealed the nodules with early enhancement in arterial phase and washout in portal or venous phase. Serum samples were obtained before TACE and approximately 7 days after the treatment, and they were preserved at −80°C until exosome extraction.

Table I.

Clinical characteristics of 75 patients pre-TACE.

Table I.

Clinical characteristics of 75 patients pre-TACE.

CharacteristicMedian (range) or number (%)
Age (years)73 (38–89)
Sex (%)
  Male49 (65)
  Female26 (35)
Liver cirrhosis (%)57 (76)
Chronic hepatitis (%)18 (24)
Etiology (%)
  HBV9 (12)
  HBV+HCV3 (4)
  HCV39 (52)
  NBNC24 (32)
BCLC stage (%)
  01 (1)
  A36 (48)
  B34 (46)
  C4 (5)
Type 2 diabetes (%)
  Positive30 (40)
  Negative45 (60)
AST (IU/l)47 (13–219)
ALT (IU/l)33 (9–220)
HbA1c (%)5.5 (4.1–8.4)
T-Bil (mg/dl)0.9 (0.3–4.2)
ALB (g/dl)3.5 (2.3–5.0)
PT (%)75 (47–118)
Plt (×104/l)11.1 (2.6–39.7)
Child-Pugh score6 (5–9)
AFP (pg/ml)15.8 (1–126234)
DCP (AU/ml)96 (7–225827)
Tumor diameter (cm)3.4 (1–19.5)
Tumor number2 (1–10)

[i] AST, aspartate aminotransferase; ALT, alanine aminotransferase; HbA1c, glycohemoglobin A1c; T-Bil, total bilirubin; ALB, albumin; PT, prothrombin time; Plt, platelet; AFP, α-fetoprotein; DCP, des-γ carboxyprothrombin, BCLC, Barcelona Clinic Liver Cancer staging classification; TACE, transarterial chemoembolization.

TACE treatment

The conventional TACE was performed using a mixture of epirubicin hydrochloride or miriplatin hydrate, mitomycin C, iodine addition products of the fatty acid ethyl esters obtained from the poppy-seed oil, and a contrast agent, administered into the tumor vessels. Subsequently, embolization was performed using gelatin sponge particles if a massive tumor thrombosis did not appear following the treatment.

Exosome isolation from human serum samples

ExoQuick (63 µl; System Biosciences, Palo Alto, CA, USA) was added to 250 µl of cell-free serum samples, and the mixture was placed at 4°C overnight. The mixture was centrifuged at 1,500 × g for 30 min and the supernatant was removed to obtain the exosome pellets. The pellets were resuspended in 300 µl of the lysis buffer for RNA isolation and 5 µl of Caenorhabditis elegans microRNA (Cel-miR-39, mirVana miRNA mimic; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was added to normalize the levels.

RNA isolation and RT-qPCR assay

MirVana miRNA Isolation Kit (Invitrogen; Thermo Fisher Scientific, Inc.) was used to isolate RNA. TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used for the reverse transcription of miRNA to cDNA, using miR-122, miR-21 and cel-miR-39 specific primers (TaqMan MicroRNA Assays; Applied Biosystems; Thermo Fisher Scientific, Waltham, Inc.).

After the synthesis of cDNA, RT-qPCR was performed by using TaqMan Universal Mastermix II (Applied Biosystems; Thermo Fisher Scientific, Inc.) and RT-qPCR reactions were performed using LightCycler 480 system II (Roche Diagnostics, Basel, Switzerland), and Cq values were calculated. The assays were performed in triplicate, and the relative quantification of miRNA expression levels was performed using the 2−ΔΔCq method (ΔCq=CqmiR-Cqcel-miR-39) (16). Because of the non-normal distribution, the logarithmic transformation of the relative expression levels of exosomal miRNAs was used for analyses. Exosomal miRNA ratio was defined as the fold change of ΔCq (miR ratio=ΔCq miR after TACE/ΔCq miR before TACE).

Statistical analysis

Clinicopathological data are presented as median (range). JMP Pro 11.2.0 (SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis. The Student's t-test was used to analyze paired data, while the correlations were analyzed using the Pearson's correlation coefficient. The cumulative survival rate was calculated using Kaplan-Meier method and the difference in the survival time between two groups was assessed with log-rank test. Univariate and multivariate Cox proportional hazard analyses were used to calculate Cox proportional hazard ratio between disease specific survival and clinical parameter. P-values were bilaterally tested, and P<0.05 was considered to indicate a statistically significant difference.

Results

TACE-induced exosomal miRNA alterations and the correlations between the pre-TACE exosomal miRNA levels and clinical parameters

Exosomal miR-122 expression levels were shown to be significantly decreased after TACE (P=0.012) (Fig. 1), but the exosomal miR-21 expression levels did not change (Fig. 2). The expression levels of exosomal miR-122 before TACE were shown to be significantly correlated with aspartate aminotransferase (AST) levels (r=0.31, P=0.004), alanine aminotransferase (ALT) levels (r=0.33, P=0.003), tumor diameter (r=0.29, P=0.010), and Child-Pugh score (r=−0.28, P=0.013; Table II). Exosomal miR-21 pre-TACE levels were shown to correlate with prothrombin time (r=0.38, P<0.001) and Child-Pugh score (r=−0.30, P=0.006; Table III).

Table II.

Correlation between pre-TACE exosomal miR-122 levels and clinical parameters.

Table II.

Correlation between pre-TACE exosomal miR-122 levels and clinical parameters.

VariablerCase numberLower 95% CIUpper 95% CIP-value
Age (years)−0.159475−0.37290.07010.172
HbA1c (%)0.152870−0.08520.37430.206
AST (IU/l)0.3144750.09420.50530.006
ALT (IU/l)0.3365750.11860.52350.003
T-Bil (mg/dl)−0.189275−0.3990.03950.104
ALB (g/dl)0.109275−0.12080.3280.351
PT (%)0.220973−0.00970.42910.060
Plt (×104/l)0.142375−0.08740.35780.223
Child Pugh score−0.283875−0.4798−0.06070.013
AFP (pg/ml)0.189375−0.03940.39910.103
DCP (AU/ml)0.219473−0.01120.42790.062
Tumor diameter (cm)0.2933750.07110.48780.010
Tumor number0.146175−0.08370.36110.211

[i] r, Pearson's correlation coefficient; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HbA1c, glycohemoglobin A1c; T-Bil, total bilirubin; ALB, albumin; CI, confidence interval; PT, prothrombin time; Plt, platelet; AFP, α-fetoprotein; DCP, des-γ carboxyprothrombin; TACE, transarterial chemoembolization.

Table III.

Correlation between pre-TACE exosomal miR-21 levels and clinical parameters.

Table III.

Correlation between pre-TACE exosomal miR-21 levels and clinical parameters.

VariablerCase numberLower 95% CIUpper 95% CIP-value
Age (years)0.048775−0.18020.27270.678
HbA1c (%)0.124270−0.11410.3490.305
AST (IU/l)0.193775−0.03480.4030.095
ALT (IU/l)0.224875−0.00230.42980.052
T-Bil (mg/dl)−0.178175−0.38930.0510.126
ALB (g/dl)0.193275−0.03530.40250.096
PT (%)0.3846730.16960.5647<0.001
Plt (×104/l)0.183175−0.04570.39370.115
Child Pugh score−0.309375−0.5011−0.08860.006
AFP (pg/ml)0.149575−0.08020.36410.200
DCP (AU/ml)0.116873−0.11640.33780.325
Tumor diameter (cm)0.126375−0.10360.34340.280
Tumor number−0.063975−0.28670.16550.586

[i] r, Pearson's correlation coefficient; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HbA1c, glycohemoglobin A1c; T-Bil, total bilirubin; ALB, albumin; CI, confidence interval; PT, prothrombin time; Plt, platelet; AFP, α-fetoprotein; DCP, des-γ carboxyprothrombin; TACE, transarterial chemoembolization.

Exosomal miR-122 and miR-21 pre-TACE expression levels did not significantly differ between the LC and chronic hepatitis groups. However, exosomal miR-122 pre-TACE expression levels were significantly higher in the Child-Pugh grade A patients than in the Child-Pugh grade B patients (ANOVA, P=0.0090). Similar results were obtained when miR-21 expression was analyzed (ANOVA, P=0.0022).

Association between clinical parameters and exosomal miRNA levels and disease-specific survival

The MST for all patients was 47 months. Univariate analysis of factors associated with survival demonstrated that Child-Pugh grade B (hazard ratio (HR), 2.495; 95% confidence interval (CI), 1.186–5.218; P=0.016), α-fetoprotein (AFP) levels >20 pg/ml (HR, 2.186; 95% CI, 1.061–4.609; P=0.034), des-gammma-carboxyprothrombin (DCP) levels >40 AU/ml (HR, 3.240, 95% CI, 1.248–11.06; P=0.013), and tumor diameter >3 cm (HR, 2.426; 95% CI, 1.132–5.637; P=0.022) represent the risk factors. Multivariate Cox proportional hazard regression results showed that Child-Pugh grade B (HR, 5.172; 95% CI, 2.194–12.586; P=0.0002), AFP >20 pg/ml (HR, 2.667; 95% CI, 1.197–6.147; P=0.0163), DCP >40 AU/ml (HR, 4.695; 95% CI, 1.674–17.051), and tumor diameter >3 cm (HR, 2.844; 95% CI, 1.266–6.931; P=0.0106) represent independent risk factors. However, exosomal miR-122 and miR-21 expression levels, exosomal miR-122 ratio, and exosomal miR-21 ratio were not shown to be associated with the disease-specific survival.

In the limited LC group (n=57), according to median exosomal miR-122 ratio, the patients with the higher ratio showed a significantly longer disease-specific survival than that observed in the group with the lower ratio (P=0.0461) (Fig. 3). No significant difference in disease-specific survival was observed between the patients with the higher and lower exosomal miR-21 ratios. Univariate Cox proportional hazards regression revealed that Child-Pugh grade B (HR, 2.372; 95% CI, 1.011–5.685; P=0.047), DCP >40 AU/ml (HR, 2.810; 95% CI, 1.046–9.763; P=0.0396), tumor diameter >3 cm (HR, 2.554; 95% CI, 1.101–6.387; P=0.0287), and the decrease in the exosomal miR-122 ratio (HR, 2.490; 95% CI, 1.028–6.689; P=0.0429) represent risk factors (Table IV). Multivariate Cox proportional hazards regression results demonstrated here that the Child-Pugh grade B (HR, 3.588; 95% CI, 1.446–9.224; P=0.006), tumor diameter >3 cm (HR, 3.606; 95% CI, 1.484–9.505; P=0.004), and lower exosomal miR-122 ratio (HR, 2.720; 95% CI, 1.035–8.022; P=0.042) represent independent factors associated with poor prognosis.

Table IV.

Factors associated with the disease-specific survival in liver cirrhosis patients (n=57).

Table IV.

Factors associated with the disease-specific survival in liver cirrhosis patients (n=57).

VariableHR (95% CI)P-valueHR (95% CI)P-value
Sex (male vs. female)0.545 (0.236–1.320)0.172
Age (years >60 vs. ≤60)0.678 (0.300–1.623)0.369
Type 2 diabetes (positive vs. negative)0.433 (0.155–1.044)0.063
HBV (positive vs. negative)2.144 (0.610–5.896)0.209
AST (>50 vs. ≤50 U/l)1.158 (0.489–2.664)0.731
ALT (>50 vs. ≤50 U/l)0.838 (0.301–2.029)0.708
Child-Pugh grade (B vs. A)2.372 (1.011–5.685)0.0473.588 (1.446–9.224)0.006
AFP (>20 vs. ≤20 pg/ml)2.225 (0.968–5.378)0.059
DCP (>40 vs ≤40 AU/ml)2.810 (1.046–9.763)0.039  2.960 (0.984–11.238)0.053
Tumor diameter (>3 vs. ≤3 cm)2.554 (1.101–6.387)0.0283.606 (1.484–9.505)0.004
Tumor number (≥2 vs. 1)1.007 (0.412–2.816)0.987
BCLC (B+C vs 0+A)1.108 (0.492–2.585)0.804
Exo miR122 (≤0.00024 vs. >0.00024)0.754 (0.329–1.743)0.502
Exo miR122 ratio (≤0.793 vs. >0.793)2.490 (1.028–6.689)0.0422.720 (1.035–8.022)0.042
Exo miR21 (≤0.00064 vs. >0.00064)1.049 (0.466–2.407)0.906
Exo miR21 ratio (≤0.82169 vs. >0.82169)1.293 (0.564–2.996)0.539

[i] Cox proportional hazards regression was performed to derive HR and CI values. HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HbA1c, glycohemoglobin A1c; T-Bil, total bilirubin; ALB, albumin; PT, prothrombin time; Plt, platelet; AFP, α-fetoprotein; DCP, des-γ carboxyprothrombin; BCLC, Barcelona Clinic Liver Cancer staging; TACE, transarterial chemoembolization.

Discussion

Treatment strategy for HCC patients requires obtaining the accurate data showing the tumor stage and residual liver function, due to the potential post-treatment liver failure. Therefore, biomarkers that may provide liver-specific information are required. Several studies analyzed the pre-treatment expression levels of exosomal miRNAs in HCC patients (17,18), however, there are no reports describing the alterations in miRNA levels after TACE. To the best of our knowledge, this is the first report showing that the exosomal miRNA ratio affects the prognosis of LC patients.

Liver function usually deteriorates after TACE, due to the damaging of the non-cancerous tissue. We showed that the post-TACE exosomal miR-122 levels significantly decreased, and no correlation between exosomal miRNA levels and conventional tumor marker levels was observed. The expression levels of miR-122 after TACE significantly inversely correlated with the Child-Pugh score (r=−0.24, P=0.0344), however, these changes did not correlate with the changes in the standard liver function tests. These results suggest that the decline in exosomal miR-122 levels may reflect a decrease in the liver function, rather than the anti-tumor effects of this procedure. In contrast, exosomal miR-21 levels were not significantly altered after TACE. A previous report showed the increased expression of serum exosomal miR-21 in HCC patients with HBV (19) but no previous studies reported the changes in the exosomal miR-21 level following the TACE treatment.

Recent studies demonstrated that the circulating miR-122 levels are associated with the liver damage and ALT levels (2023). In our study, the expression levels of serum exosomal miR-122 before TACE were shown to correlate significantly with AST and ALT levels,. Pre-TACE exosomal miR-122 levels were shown to be negatively correlated with the Child-Pugh score, indicating that the expression levels of exosomal miR-122 reflect liver function and liver fibrosis rate. In our previous study, we showed that a decrease in serum miR-122 levels correlates with the development of severe fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (24), while Morita et al (25) showed that the hepatic miR-122 levels in patients with HCV are negatively correlated with the functional liver damage. If exosomal miRNA levels mirror those in the parental cells, the obtained result may indicate that the exosomal miR-122 levels reflect residual liver function and capacity.

Pre-TACE expression levels of exosomal miR-122 did not significantly differ between the chronic hepatitis and LC patient groups. miR-122 was shown to be associated with the liver fibrosis rate (24,26,27) and viral replication rate (2830) and therefore, the heterogeneous patient background may affect the obtained results. Furthermore, no significant correlation was observed between the expression levels of exosomal miR-21 and the BCLC stage. Exosomal miR-21 levels were shown to be associated with prothrombin time and Child-Pugh score, and therefore, this molecule can represent a less specific prognostic biomarker than exosomal miR-122 in HCC patients.

The mechanisms of action and functions of miR-122, especially post-treatment, are not well-known. In hypoxic condition after embolization, this molecule may induce hypoxia inducible factor 1α (HIF-1α) expression in non-cancerous liver tissue and cancer cells. HIF-1α and vimentin represent miR-122 targets in hepatocytes (31), while the reduced liver miR-122 levels were shown to be associated with increased HIF-1α levels in the diet-induced steatohepatitis mouse model. There is a possibility that the changes in miR-122 levels are associated with epithelial-mesenchymal transition (EMT), however, we were not able to show whether the EMT is associated with decline of miR-122 in this study. A recent study demonstrated that miR-122 inhibits the EMT by targeting Snail and WNT/β-cadherin signaling pathway (32). Additionally, miR-122 plays a key role in mitochondrial metabolism by indirectly regulating mitochondrial genes (33), such as PPARGC1A (PGC-1a). The loss of miR-122 can result in a damaged liver function (33) and it was shown to be associated with the HCC patient mortality.

In all patients, exosomal miR-122 and miR-21 levels, and miRNA ratios were not shown to be independent factors associated with the disease-specific survival. However, in HCC patients with LC, lower exosomal miR-122 ratio was shown to be an independent factor for poor prognosis. A previous report showed that serum miR-122 levels negatively correlate with the model of end-stage liver disease (MELD) score (34) and are associated with poor prognosis in decompensated liver disease patients (35). Moreover, in HCV-induced fibrosis, the decrease in circulating miR-122 reflects the development of liver fibrosis and the loss of viable liver cells (36). Therefore, liver fibrosis contributes to the liver function decline, and our results indicate that exosomal miR-122 levels, especially in LC patients, may serve as important post-TACE predictive biomarkers. Since a considerably higher decline in exosomal miR-122 levels after TACE occurs in patients with LC than in those with chronic hepatitis, we hypothesize that the group with a more prominent decrease in exosomal miR-122 levels after TACE has a lower survival rate.

Several limitations of this study should be noted. To determine tumor-specific exosomal miRNAs, exosomal miRNA levels in the sera of patients without HCC, but with chronic liver diseases, should be determined. Our study was retrospective, with a somewhat small sample size, and it included advanced chronic hepatitis cases, because all patients with preserved liver function underwent the surgical procedure.

In conclusion, exosomal miR-122 levels may reflect the liver damage and residual liver function levels. This is the first report showing that the post-TACE expression levels of exosomal miR-122 decrease, especially in the LC patients. Additionally, lower miR-122 ratio was shown to be associated with poor prognosis. Serum exosomal miRNA levels after treatment may represent novel biomarkers guiding the decision-making during the treatment of HCC patients.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

HM designed the study, developed the methodology and reviewed the final version of the manuscript. TS performed data analyses, curated and visualized data, and wrote the first draft. TS and YK performed the experiments. KN supervised the study. All authors read and approved the final version of the manuscript. Resources: HS, TH, EO, SM, NT and KN. HS, TH, EO, SM, NT and KN contributed to the acquisition and interpretation of data

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee of Nagasaki University Hospital (no. 16042513), and informed consent was obtained from all patients.

Consent for publication

Written informed consents was obtained from all patients included in the study.

Competing interests

The authors declare that they have no competing interests.

References

1 

Hashim D, Boffetta P, La Vecchia C, Rota M, Bertuccio P, Malvezzi M and Negri E: The global decrease in cancer mortality: Trends and disparities. Ann Oncol. 27:926–933. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI

3 

Sangiovanni A and Colombo M: Treatment of hepatocellular carcinoma: Beyond international guidelines. Liver Int. 36 Suppl 1:S124–S129. 2016. View Article : Google Scholar

4 

Han K and Kim JH: Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 21:10327–10335. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Murata S, Mine T, Ueda T, Nakazawa K, Onozawa S, Yasui D and Kumita S: Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal. 2013:4798052013. View Article : Google Scholar : PubMed/NCBI

6 

Peck-Radosavljevic M: Drug therapy for advanced-stage liver cancer. Liver Cancer. 3:125–131. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Girard M, Jacquemin E, Munnich A, Lyonnet S and Henrion-Caude A: miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol. 48:648–656. 2008. View Article : Google Scholar : PubMed/NCBI

9 

Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J and Meng S: Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 7:17021–17034. 2016.PubMed/NCBI

10 

Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, et al: miR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 69:5761–5767. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 49:1571–1582. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI

13 

Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, et al: Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 14:3192013. View Article : Google Scholar : PubMed/NCBI

14 

Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, et al: Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 113:275–281. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, et al: Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 129:2429–2436. 2017. View Article : Google Scholar : PubMed/NCBI

16 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

17 

Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, et al: Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. PLoS One. 10:e01414482015. View Article : Google Scholar : PubMed/NCBI

18 

Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, Shim SG and Paik YH: Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 47:e1842015. View Article : Google Scholar : PubMed/NCBI

19 

Wang H, Hou L, Li A, Duan Y, Gao H and Song X: Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014:8648942014.PubMed/NCBI

20 

Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, Zheng J, Liang Z, Hu Z and Du Q: Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep. 5:1428–1432. 2012.PubMed/NCBI

21 

Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL, Sistare FD, et al: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem. 55:1977–1983. 2009. View Article : Google Scholar : PubMed/NCBI

22 

Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K and Szabo G: Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 56:1946–1957. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, et al: Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 106:1663–1669. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L and Nakao K: Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 34:e302–e307. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Morita K, Taketomi A, Shirabe K, Umeda K, Kayashima H, Ninomiya M, Uchiyama H, Soejima Y and Maehara Y: Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int. 31:474–484. 2011. View Article : Google Scholar : PubMed/NCBI

26 

Nakao K, Miyaaki H and Ichikawa T: Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z and Lendvai G: miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol. 21:7814–7823. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Conrad KD, Giering F, Erfurth C, Neumann A, Fehr C, Meister G and Niepmann M: MicroRNA-122 dependent binding of Ago2 protein to hepatitis C virus RNA is associated with enhanced RNA stability and translation stimulation. PLoS One. 8:e562722013. View Article : Google Scholar : PubMed/NCBI

29 

Sendi H: Dual role of miR-122 in molecular pathogenesis of viral hepatitis. Hepat Mon. 12:312–314. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Jangra RK, Yi M and Lemon SM: Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol. 84:6615–6625. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Csak T, Bala S, Lippai D, Satishchandran A, Catalano D, Kodys K and Szabo G: microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 35:532–541. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Jin Y, Wang J, Han J, Luo D and Sun Z: miR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway. Exp Cell Res. 360:210–217. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI

34 

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A and Waidmann O: Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 49:3442–3449. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Waidmann O, Köberle V, Brunner F, Zeuzem S, Piiper A and Kronenberger B: Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One. 7:e456522012. View Article : Google Scholar : PubMed/NCBI

36 

Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, et al: Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol. 58:234–239. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Suehiro T, Miyaaki H, Kanda Y, Shibata H, Honda T, Ozawa E, Miuma S, Taura N and Nakao K: Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients. Oncol Lett 16: 3267-3273, 2018.
APA
Suehiro, T., Miyaaki, H., Kanda, Y., Shibata, H., Honda, T., Ozawa, E. ... Nakao, K. (2018). Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients. Oncology Letters, 16, 3267-3273. https://doi.org/10.3892/ol.2018.8991
MLA
Suehiro, T., Miyaaki, H., Kanda, Y., Shibata, H., Honda, T., Ozawa, E., Miuma, S., Taura, N., Nakao, K."Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients". Oncology Letters 16.3 (2018): 3267-3273.
Chicago
Suehiro, T., Miyaaki, H., Kanda, Y., Shibata, H., Honda, T., Ozawa, E., Miuma, S., Taura, N., Nakao, K."Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients". Oncology Letters 16, no. 3 (2018): 3267-3273. https://doi.org/10.3892/ol.2018.8991